
BioLife Solutions (BLFS) Stock Forecast & Price Target
BioLife Solutions (BLFS) Analyst Ratings
Bulls say
BioLife Solutions is expected to continue its strong performance with 18 unique commercial cell & gene therapy products, with potential for regulatory approvals of 8 more products in the next 12 months. Despite a slight decrease in gross margins, the company's adjusted EBITDA increased over 30%, reflecting strong financial health. With a solid cash position of $113.1 million and an anticipated acquisition by Repligen, shares are fairly valued at $31 with a Hold rating. Investment risks include regulatory hurdles, competition, and potential delays or weaknesses in the acquisition process.
Bears say
BioLife Solutions is a life sciences company with a negative outlook due to challenges in the biopreservation market and a recent divestiture of non-core units, leading to lower financial projections. Additionally, the company's acquisition by Repligen may not provide enough value to shareholders and could lead to integration issues. There are also risks within the medical and life science sector, such as reduced R&D budgets, government funding, and regulatory hurdles, that could negatively impact BioLife's revenue.
This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.
BioLife Solutions (BLFS) Analyst Forecast & Price Prediction
Start investing in BioLife Solutions (BLFS)
Order type
Buy in
Order amount
Est. shares
0 shares